Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆijªÁø     (Date : 2010-09-14 11:15:58)
À̸ÞÀÏ info@panagene.com
Á¦¸ñ [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥]Peptide nucleic acid array for detection of point mutations in hepatitis B virus associated with antiviral resistance.
³»¿ë

PNAÀÇ ÀåÁ¡ Áß Çϳª´Â SNP¸¦ ±¸ºÐÇÏ´Â ´É·ÂÀÌ Å¹¿ùÇÏ´Ù´Â °ÍÀÔ´Ï´Ù.
BÇü °£¿°À» ÀÏÀ¸Å°´Â HBVÀÇ °æ¿ì, µ¹¿¬º¯À̸¦ ÀÏÀ¸Å°¸ç ¿©·¯°¡Áö ¾àÁ¦¿¡ ´ëÇØ ³»¼ºÀ» °¡Áö°Ô µÇ¹Ç·Î, ÀûÀýÇÑ Ã³¹æÀ» À§ÇÏ¿© HBV ¹ÙÀÌ·¯½ºÀÇ µ¹¿¬º¯ÀÌ °ËÃâ±â¼úÀÌ ÇʼöÀûÀÔ´Ï´Ù.
(ÁÖ)ÆijªÁøÀº PNA ChipÀ» ÀÌ¿ëÇÏ¿© ¾àÁ¦ ³»¼ºÀ» ÀÏÀ¸Å°´Â HBVÀÇ µ¹¿¬º¯À̸¦ ³ôÀº ¹Î°¨µµ¿Í ƯÀ̵µ·Î °ËÃâÇÒ ¼ö ÀÖ´Â ±â¼úÀ» °³¹ßÇÏ¿´½À´Ï´Ù.


J Clin Microbiol. 2010 Sep;48(9):3127-31. Epub 2010 Jun 23.

Peptide nucleic acid array for detection of point mutations in hepatitis B virus associated with antiviral resistance.

Jang H, Kim J, Choi JJ, Son Y, Park H.

Panagene Inc., 816 Tamnip-Dong, Youseong-Gu, Daejeon, 305-510, South Korea.

Abstract

The detection of antiviral-resistant hepatitis B virus (HBV) mutations is important for monitoring the response to treatment and for effective treatment decisions. We have developed an array using peptide nucleic acid (PNA) probes to detect point mutations in HBV associated with antiviral resistance. PNA probes were designed to detect mutations associated with resistance to lamivudine, adefovir, and entecavir. The PNA array assay was sensitive enough to detect 10(2) copies/ml. The PNA array assay was able to detect mutants present in more than 5% of the virus population when the total HBV DNA concentration was greater than 10(4) copies/ml. We analyzed a total of 68 clinical samples by this assay and validated its usefulness by comparing results to those of the sequencing method. The PNA array correctly identified viral mutants and has high concordance (98.3%) with direct sequencing in detecting antiviral-resistant mutations. Our results showed that the PNA array is a rapid, sensitive, and easily applicable assay for the detection of antiviral-resistant mutation in HBV. Thus, the PNA array is a useful and powerful diagnostic tool for the detection of point mutations or polymorphisms.


Link to paper  => Click


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆijªÁø 30439
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆijªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆijªÁø 29344
   46           [³í¹®] [2015]Simultaneous genoty.. ÆijªÁø 6202
   45           [³í¹®] [2014]Simultaneous diagno.. ÆijªÁø 21108
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆijªÁø 8549
   43           [³í¹®] [2013]Detection of EGFR m.. ÆijªÁø 1308
   42           [³í¹®] [2013]Detection and compa.. ÆijªÁø 5950
   41           [³í¹®] [2013]Detection of BRAF V.. ÆijªÁø 6232
   40           [³í¹®] [2013]Comparison of Direc.. ÆijªÁø 25419
   39           [³í¹®] [Microarray]Peptide nucle.. ÆijªÁø 14456
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆijªÁø 22375
   37           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆijªÁø 3521
   36           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆijªÁø 14292
   35           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆijªÁø 1300
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆijªÁø 4162
   33           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆijªÁø 8956
   32           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆijªÁø 14611
   31           [³í¹®] [ÆijªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆijªÁø 1304
¢º           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆijªÁø 4026
 

< 1 2 3 >